Gilead Sciences to Present at Two Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--June 9, 2006--Gilead Sciences, Inc. (Nasdaq:GILD):

  • Pacific Growth Equities -- Life Sciences Growth Conference on June 13th
  • 27th Annual Goldman Sachs Global Healthcare Conference on June 14th
  • Webcasts Available Through Gilead Corporate Website

Gilead Sciences, Inc. (Nasdaq:GILD) announced today that its corporate presentation will be webcast at two upcoming investor conferences: the Pacific Growth Equities -- Life Sciences Growth Conference, in San Francisco, California, and the 27th Annual Goldman Sachs Global Healthcare Conference, in Dana Point, California. These webcasts may be accessed via the company's corporate website at www.gilead.com.

Mark Perry, Gilead's Senior Business Advisor, will provide an overview of the company and an update on key business milestones at the Pacific Growth conference on Tuesday, June 13th at 4:00 p.m. Eastern Time.

John Milligan, PhD, Gilead's Executive Vice President and Chief Financial Officer, will provide an overview of the company and an update on key business milestones at the Goldman Sachs conference on Wednesday, June 14th at 3:00 p.m. Eastern Time.

To access the live webcasts via the internet log on to www.gilead.com. Please connect to the company's website at least 15 minutes prior to each live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715
SOURCE: Gilead Sciences, Inc.